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1. Introduction 
Recently, an elastolytic protease has been isolated 
from human polymorphonuclear (PMN) leukocyte 
granule fractions and purified by affinity chromato- 
graphy [ 11. This human leukocyte elastase is known 
to degrade human lung elastin, arterial walls and base- 
ment membrane, digest proteins of bacterial cell walls 
in vitro, induce cellular surface changes correlated with 
loss of growth control, and undergo inhibition by cyI - 
antitrypsin and peptide chloromethyl ketones [2]. A 
growing body of experimental evidence has suggested 
that this elastase may be involved in pathological pro- 
cesses associated with elastic tissue damage in pulmo- 
nary emphysema and acute arteritis, and with the 
tumor-producing action of cocarcinogenic substances 
[3]. Peptide chloromethyl ketones are well-known 
inhibitors of serine proteases which have proved quite 
useful for structural studies, including X-ray crystallo- 
graphic investigations, of the active site regions of this 
group of enzymes [4]. A series of alanine tri- and 
tetrapeptide chloromethyl ketone inhibitors was 
synthesized by us and two other groups to probe the 
nature of the extended binding site and catalytic 
activity of porcine pancreatic elastase (EC 3.4.2 1 .l 1) 
and related enzymes [5,6 1. In this paper we report 
a study of the inhibition of human leukocyte elas- 
tase by a series of peptide chloromethyl ketones, 
which demonstrates that the human leukocyte enzyme 
is distinct from the porcine pancreatic enzyme. The 
results also define the structural features necessary 
for an effective inhibitor and may lead to a treatment 
for emphysema and related diseases. 
* To whom requests for reprints should be sent. 
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2. Materials and methods 
Human leukocyte elastase was 85% pure as deter- 
mined by a gel densitometry scan and contained one 
major and two minor elastase isoenzymes. Inhibition 
reactions were performed by rapidly mixing elastase 
and inhibitor solutions in 0.1 M phosphate, pH 6.5, 
at 25”C, and allowing the reaction to proceed through 
at least two half-lives. Final concentrations were: 
elastase, 10 PM; tripeptide inhibitor, 1 mM (or tetra- 
peptide inhibitor, 0.2 mM); CaClz, 0.1 mM; methanol, 
5% v/v; in a total volume of 0.3 1 ml. These conditions 
were chosen to minimize the enzyme consumed and 
to facilitate kinetic measurements. Enzyme assays were 
periodically performed on aliquots containing 12.5 pg 
elastase using the BOC-Ala-ONp spectrophotometric 
assay method at 345 nm [7]. Kinetic results for each 
inhibitor were calculated from the equation 
I/. r&it&ion = k&&(E) = k2nd (I) (E) 
with the aid of a line-fitting computer program, and 
are presented in table 1. The second-order rate constant 
kobti/(I) is suitable only for purpose of approximate 
reactivity comparisons among the inhibitors, since 
kobd/(I) becomes non-linear with (I) when (I) becomes 
close to K,, the dissociation constant of the enzyme- 
inhibitor complex [5]. Due to the small amount of 
enzyme available we were unable to carry out concen- 
tration-dependent inhibition studies to determine K, 
values. Slight problems of reproducibility arose from 
a lack of enough enzyme for duplicating all inhibition 
runs, but the correlation coefficients for all runs were 
greater than 0.99. 
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Table 1 
Inhibition of human leukocyte elastase with peptide chloromethyl ketones 
-___ ____~~~ 
Inhibitor (I) 104*kobsd 10’kobsd/(L) kobsd/(L) kobsd/(t)* 
P4 Pa Pz PI (mM) (set-’ ) (M-l set-’ ) (rel.) (rel.) 
-___ 
AC-Ala- Ala-AlaCH, Cl 1 .O 2.8** 2.8 1.0 1.0 
Ac-Ala-Pro-AlaCH,Cl 1.0 10.9 10.9 4.0 1.6 
Ac-Pro-Ala-AlaCH,Cl 1.0 0 0 0 0 
Z-Gly-Leu-AlaCH, Cl 1.0 20.2 20.2 7.3, 1.9 
Z-Gly-Leu-PheCH, Cl 1.0 0 0 0 _ 
Ac-Ala-Ala-Ala-AlaCH, Cl 0.2 2.0** 9.7 3.5 18 
Ac-Ala-Ala-Pro-AlaCH, Cl 0.2 8.7** 43.6 15.8 71 
Ac-Ala-Pro-Ala-AlaCH,C1 0.2 4.4 22.2 8.1 0 
Ac-Ala-Ala-Phe-AlaCH,C10.2 2.6 13.2 4.8 16 
Ac-Phe-Gly-Ala-LeuCH,ClO.2 1.2 6.0 2.2 _ 
* Data for porcine pancreatic elastase [ 51. 
** Average of two runs. 
Elastase concentration 10 PM, at pH 6.5,25”C, 5% methanol. 
3. Results and discussion 
A comparison of the effectiveness of the peptide 
chloromethyl ketone inhibitors, based on their relative 
kobsd/(I) values, leads to several interesting relationships 
between the structure of inhibitors and reactivity toward 
human leukocyte elastase. The tetrapeptides were 
usually observed to be faster inhibitors than the tripep- 
tides and were run at S-fold lower inhibitor concentra- 
tions (I). Ac-Ala-Ala-Pro-AlaCH2 Cl is the best 
leukocyte elastase inhibitor of the series. In general the 
tetrapeptides are about 3 to 4 times more reactive than 
the tripeptides, which is evidence for the inhibitors’ 
interaction with an extended binding site in leukocyte 
elastase. The Pr residue [S] is alanine in almost all of 
the inhibitors, e.g. Ac-Ala-Ala-Ala-Al&H2 Cl, 
corresponding to the substrate specificity of elastase 
for alanine and other amino acids with small side 
chains. If Pr is phenylalanine, as in the chymotrypsin 
inhibitor Z-Gly-Leu-PheCH2C1, no leukocyte elastase 
inhibition is observed, whereas if Pr is leucine, as in the 
potent subtilisin inhibitor Ac-Phe-Gly-Ala-LeuCH2 Cl, 
a small rate of elastase inhibition takes place. In the 
Pz position, proline appears to be favored over alanine: 
kobsd/(I) for Ac-Ala-Ala-Pro-AlaCHz Cl is 4 to 5 
times larger than for Ac-Ala-Ala-Mu--CH2 Cl, and this 
also holds true for the analogous tripeptide pair. A 
leucine in Pz is also favorable as in Z-Gly-Leu- 
AlaCH?Cl, but a phenylalanine in Pe is little better 
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than alanine: compare Ac-Ala-Ala-Phe-AlaCHe Cl 
with Ac-Ala-Ala-Ala-AlaCHa Cl. Thus human 
leukocyte elastase may possibly exhibit a weak secon- 
dary specificity for inhibitors with P2 residues possess- 
ing medium-sized alkyl side chains (4). If the Pa residue 
is proline as in the tripeptide inhibitor Ac-Pvo-Ala- 
Ala-CHe Cl, no inhibition of leukocyte elastase is 
observed. But if Pa is proline as in the tetrapeptide 
inhibitor Ac-Ala-Pro-Ala-Ala-CHe Cl, elastase 
inhibition does occur. Ac-Ala-Pro-Ala-Ala-CH2 Cl 
is a non-inhibitor toward porcine pancreatic elastase 
[5]. In the P4 position a large hydrophobic group, 
e.g. phenyl, appears to be beneficial although further 
studies will be necessary for verification. This could 
explain the higher than expected activity of Z-Gly- 
Leu-AlaCHz Cl and Ac-Phe-Gly-Ala-LeuCH2 Cl, 
both of which possess a benzyl side chain at P4, toward 
leukocyte elastase. For optimum reactivity, a leukocyte 
elastase inhibitor should contain a Pr alanine, a Pz 
proline or leucine, no Pa proline (in the case of tri- 
peptides), and possibly a P4 phenylalanine. 
At this point, it is of interest to examine certain 
inhibition characteristics of human leukocyte elastase 
as compared to the more thoroughly studied porcine 
pancreatic elastase [5]. First of all, leukocyte elastase 
reacts less rapidly overall with this group of peptide 
chloromethyl ketones than does pancreatic elastase, 
as indicated by smaller values of kobsd/(I) for inhibi- 
tion. Secondly, the increase in reactivity toward inhi- 
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bitors in going from tripeptides to tetrapeptides is 
smaller in the case of leukocyte elastase, which may 
indicate differences in the geometry of the extended 
binding sites and the effect of the individual subsites 
on the catalytic activity of these two enzymes. Thirdly, 
the derived structure-reactivity relationships are 
generally parallel between the inhibitors and the two 
kinds of elastase, with regard to the structural features 
required for enhancement of elastase inhibition. 
Finally, Ac-Ala-Ala-Pro-AlaCH* Cl is the most 
effective inhibitor tested for both human leukocyte 
and porcine pancreatic elastase. Interestingly, its isomer 
Ac-Ala-Pro-Ala-AlaCHz Cl is a relatively good inhi- 
bitor for the leukocyte enzyme but is not effective 
to touch the pancreatic enzyme, which is strong 
evidence that the leukocyte and pancreatic enzymes 
are distinct entities. 
In conclusion, this initial kinetic study of human 
leukocyte elastase clearly demonstrates the value of 
peptide chloromethyl ketones as active-site directed 
inhibitors for this enzyme in providing structure-reac- 
tivity correlations. At present a number of investiga- 
tors have begun in vivo enzymatic studies with these 
inhibitors and they should prove useful for elucidating 
many of the molecular pathways by which human 
leukocyte elastase carries out its physiological and 
pathological functions. 
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